Zheng Quan Zhi Xing·2025-07-16 11:12Summary of Key Points Core Viewpoint - Shanghai Yizhong Pharmaceutical Co., Ltd. is planning a share transfer through a pricing inquiry, with the selling party being Shanghai Kaibao Pharmaceutical Co., Ltd. This transfer involves 2,067,037 shares, representing 1.00% of the total share capital, primarily due to the seller's funding needs [1][2][3]. Group 1: Shareholder Information - The selling party, Shanghai Kaibao, holds 2,067,037 shares, which is 8.37% of its total holdings in Shanghai Yizhong [3]. - The selling party is not a controlling shareholder, actual controller, or a member of the board or senior management of Shanghai Yizhong [1][2]. Group 2: Transfer Details - The shares being transferred have been released from restrictions and are free of any transfer limitations [2]. - The transfer will not occur through centralized bidding or block trading, and the shares acquired through this inquiry cannot be transferred within six months [3][4]. Group 3: Pricing and Transfer Conditions - The minimum transfer price will be set at no less than 70% of the average trading price over the 20 trading days prior to July 16, 2025 [4]. - The pricing will be determined based on a priority system that considers bid price, bid quantity, and the time of bid submission [4][5]. Group 4: Investor Eligibility - Eligible investors for this transfer include institutional investors with appropriate pricing capabilities and risk tolerance, such as securities companies, fund management companies, and qualified foreign institutional investors [5]. Group 5: Company Risk and Control - Shanghai Yizhong does not face any operational risks that require disclosure under the relevant stock exchange rules [6]. - The share transfer is not expected to lead to any change in control of Shanghai Yizhong [6].